Opinion
Video
Management of Recurrent C Difficile Infections in the Future
Author(s):
Key Takeaways
- Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
- Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
Video content above is prompted by the following:
- How do you see the management of recurrent C difficile infections moving forward?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
